YUNGJIN PHARM. CO., LTD
Financials
Valuation Metrics
YUNGJIN PHARM. CO., LTD's Market Cap is ₩1727B. At end of 2025 it was ₩3658B. Ranked #894 of 2,410 in KR market (top 37%), #477 of 779 on KOSPI (top 61%), #104 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.65B KRW | KR#894/2,410 Sec#104/231 |
| Revenue | 253.00B KRW | KR#909/2,410 Sec#47/231 |
| Net Income | -6.26B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 227.40B KRW | KR#1,221/2,410 Sec#87/231 |
| Net Assets | 86.16B KRW | KR#1,524/2,410 Sec#120/231 |
| Employees | 628 | KR#400/2,410 Sec#34/231 |
| Value | ||
| P/B | 2.00x | KR#1,984/2,410 Sec#149/231 |
| P/S | 0.68x | KR#1,176/2,410 Sec#57/231 |
| FCF Yield | 0.32% | KR#1,192/2,410 Sec#90/231 |
| Profitability | ||
| ROE | -7.26% | KR#1,868/2,410 Sec#135/231 |
| ROA | -2.75% | KR#1,812/2,410 Sec#127/231 |
| Op. Margin | -1.71% | KR#1,719/2,410 Sec#117/231 |
| Revenue Growth | 0.60% | KR#1,484/2,410 Sec#148/231 |
| Financial Health | ||
| Debt Ratio | 163.93% | KR#1,969/2,410 Sec#210/231 |
| Total Debt | 76.13B KRW | KR#829/2,410 Sec#54/231 |
| FCF | 545.9M KRW | KR#1,178/2,410 Sec#91/231 |
| Cash | 3.59B KRW | KR#2,118/2,410 Sec#200/231 |
| Current Ratio | 1.47x | KR#1,225/2,410 Sec#131/231 |
| Performance | ||
| 1Y Return | -54.17% | KR#2,063/2,410 Sec#187/231 |
| 1M Return | -9.49% | KR#1,201/2,410 Sec#120/231 |
| From 52W High | -59.31% | KR#1,627/2,410 Sec#137/231 |
| 1Y MDD | -57.10% | KR#1,291/2,410 Sec#110/231 |
| Trading | ||
| Volume | 178,838 shares | KR#238/2,410 Sec#18/231 |
| Trading Value | 167.1M KRW | KR#1,031/2,410 Sec#113/231 |
| Foreign Own. | 2.85% | KR#1,332/2,410 Sec#120/231 |
| Per Share | ||
| EPS | -34 KRW | KR—/2,410 Sec—/231 |
| BPS | 471 KRW | KR#2,374/2,410 Sec#226/231 |
Company Info
Youngjin Pharm was established in 1962 for pharmaceutical manufacturing and sales, and listed in 1973, playing a pivotal role as an affiliate of the KT&G Group. The company sells specialty pharmaceuticals such as 'Harmonylan' and 'Fivero', exports antibiotics and raw materials, and aims to strengthen its competitiveness in domestic and international markets. Youngjin Pharm secures growth engines through R&D investment and leads fair and transparent ethical management via a self-compliance program and ISO37001 certification. Its headquarters are in Songpa-gu, Seoul Metropolitan City.